Evidence map›Paper›PMID 35200650›Full record

ArticleMarine drugs2022

Anti-Inflammatory Activity of Orally Administered

Masahiro Terasawa, Keiichi Hiramoto, Ryota Uchida, Koji Suzuki

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Masahiro TerasawaFaculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Minamitamagaki-cho 3500-3, Suzuka 513-8670, Mie, Japan.ORCID 0000-0003-1250-1569
Keiichi HiramotoFaculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Minamitamagaki-cho 3500-3, Suzuka 513-8670, Mie, Japan.
Ryota UchidaFaculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Minamitamagaki-cho 3500-3, Suzuka 513-8670, Mie, Japan.
Koji SuzukiFaculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Minamitamagaki-cho 3500-3, Suzuka 513-8670, Mie, Japan.
Suzuka University of Medical Science · JP

Funding

Japan Society for the Promotion Science, Grant-in-Aid for Challenging Exploratory Research 18H05299Japan Society for the Promotion Science, Grant-in-Aid for Scientific Research (C) 19K08850
6 · The paper itself

Abstract

We previously reported that rhamnan sulfate (RS) purified from

Indexed as

Administration, OralAnimalsAnti-Inflammatory AgentsChlorophytaDeoxy SugarsEndothelium, VascularGlycocalyxInflammationLipopolysaccharidesMaleMannansMiceMice, Inbred BALB CNeutrophilsAnti-Inflammatory AgentsDeoxy SugarsLipopolysaccharidesMannansrhamnananti-inflammationendotheliumglycocalyxMonostroma nitidumrhamnan sulfate

Identifiers

PMID35200650
PMCPMC8875490
OpenAlexW4210652224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.